 Shares of Axcella Therapeutics Inc. AXLA, 6.79 gained 10.9 in premarket trading on Thursday after the biotech said its experimental treatment for nonalcoholic steatohepatitis NASH showed statistically significant improvement in liver stiffness at 24 weeks. The Phase 2b trial is ongoing. 